In the picturesque region of Austrian Tyrol lies Kundl, home to the only penicillin production plant in Europe<\/strong>. This facility is not just significant for its singularity; it represents the pride of Sandoz, which touts itself as \u201cthe only vertically integrated antibiotic manufacturer in the West.\u201d As Chairman Gilbert Ghostine emphasized in an interview, the plant’s existence becomes increasingly vital amidst concerns regarding European self-sufficiency in antibiotic manufacturing.<\/p>\n Sandoz has a long history, celebrating 140 years of heritage, with a robust position in antibiotics for the past 80 years. However, the firm underscores a pressing issue: Europe must push for self-sufficiency in drug production to ensure jobs and secure supply chains. The Draghi report has drawn attention to this necessity, suggesting that legislation could mandate that at least a third of supplies originate from European manufacturers. Ghostine argues that this not only supports local laboratories and patients but also reduces environmental impact compared to importing from abroad.<\/p>\n Faced with aggressive price dumping by foreign competitors, particularly from China and India, Sandoz has taken action. The company recently lodged a draft antidumping complaint<\/strong> with the European Commission against Chinese imports of amoxicillin, a penicillin derivative. Price reductions of up to 57% in just one year raise concerns of unsustainable market practices. Ghostine argues that allowing such dumping could lead to Europe\u2019s over-dependence on a single market, threatening the viability of local production.<\/p>\n The impeccable control Sandoz maintains over its production process is a reassuring factor for European patients and regulatory bodies. Ghostine states, \u201cSandoz is the only vertically integrated manufacturer of penicillin antibiotics in Europe,\u201d<\/strong> producing its own Active Pharmaceutical Ingredients (APIs). In contrast, 90% of APIs are sourced from outside Europe, mainly from China. This vertical integration, while costly, provides a security framework that is crucial for maintaining high-quality standards.<\/p>\n Sandoz advocates for prompt legislative reforms to better protect the European pharmaceutical industry. Ghostine highlighted how countries like India have already established measures, such as minimum price regulations for APIs, to protect local manufacturers from global price undercutting. This strategic awareness is paramount; Ghostine likens the importance of the pharmaceutical industry to other critical sectors like defense and technology, calling for heightened attention from European governments.<\/p>\n Kundl has seen a doubling of its production capacity since 2021, now manufacturing 240 million doses annually for Europe. Spain plays a pivotal role in Sandoz\u2019s operations, with headquarters in Madrid and a production plant in Palafolls, Barcelona. As the pharmaceutical industry anticipates a \u201cgolden decade\u201d with a $650 billion value in original drugs going off patent, the strategic positioning and capability of Sandoz in Spain seem vital.<\/p>\n As Sandoz champions the \u201cmade in Europe\u201d ethos, it emphasizes the importance of local production in ensuring the security of supply, promoting job creation, and maintaining environmental standards. The call for supportive legislation and protective measures highlights the urgent need for a cohesive European strategy in pharmaceutical self-sufficiency. Understanding these dynamics is crucial for navigating the future landscape of antibiotic production in Europe.<\/p>\nThe Case for European Antibiotic Production<\/h3>\n
Sandoz’s Antidumping Measures<\/h3>\n
Ensuring Security of Supply<\/h3>\n
Calls for Legislative Action<\/h3>\n
The Role of Spain in Sandoz\u2019s Vision<\/h3>\n
Conclusion<\/h3>\n